A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Cologne

About this trial

This is a prospective, multicenter, observational study (mEX-TB study) of patients with extrapulmonary tuberculosis (EPTB). Adult patients newly diagnosed with EPTB will prospectively be enrolled into the study. Clinical data will be collected using standardized questionnaires over the whole treatment period for each individual. Additionally, body fluids (blood, urine) will be collected and stored in a central biobank. Biomarkers in EPTB patients will be analyzed during the course of therapy and correlated with clinical data. In addition, a healthy control group will be added, to be used primarily as technical controls for complex laboratory procedures such as RNA-seq and T-cell based assays.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Isolation of Mycobacterium tuberculosis complex from a bodily secretion or tissue by

PCR

culture or a presumptive clinical diagnosis based on epidemiologic exposure in combination with physical findings, radiographic findings and/or histopathology

Disqualifiers

1. Age <18 years 2. Patient with any social or logistical condition which, as anticipated by the investigator, may interfere with the conduct of the study, such as incapacity to well understand the study content and procedure (in case of any language barriers, a translator may be involved), not willing to collaborate, or anticipated inability to finish study due to physical weakness 3. Dependencies towards the study team (e.g. family members, employees of the same department) 4. Pregnant women 5. Patient in custodianship or guardianship 6. Leading pulmonary manifestation 7. Solitary CNS tuberculosis Patients may take part in other clinical studies and trials, as long as there is no conflict with the inclusion or exclusion criteria of the mEX-TB study and the protocol of the other study or trial does not conflict with the means of data and sample collection and publication of this protocol.

Trial design

Treatments tested in this trial

  • biomarker analysis

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Cologne

Lead sponsor

University Hospital, Bonn

Collaborator

Research Center Borstel

Collaborator

Johann Wolfgang Goethe University Hospital

Collaborator

Universitätsklinikum Hamburg-Eppendorf

Collaborator

University Hospital Heidelberg

Collaborator

Helmholtz Zentrum München

Collaborator

University Hospital of Cologne

Collaborator